1. Home
  2. NETD vs DERM Comparison

NETD vs DERM Comparison

Compare NETD & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NETD
  • DERM
  • Stock Information
  • Founded
  • NETD 2023
  • DERM 2014
  • Country
  • NETD United States
  • DERM United States
  • Employees
  • NETD N/A
  • DERM N/A
  • Industry
  • NETD
  • DERM Biotechnology: Pharmaceutical Preparations
  • Sector
  • NETD
  • DERM Health Care
  • Exchange
  • NETD Nasdaq
  • DERM Nasdaq
  • Market Cap
  • NETD 242.3M
  • DERM 213.6M
  • IPO Year
  • NETD 2023
  • DERM 2021
  • Fundamental
  • Price
  • NETD $11.55
  • DERM $7.85
  • Analyst Decision
  • NETD
  • DERM Strong Buy
  • Analyst Count
  • NETD 0
  • DERM 3
  • Target Price
  • NETD N/A
  • DERM $12.67
  • AVG Volume (30 Days)
  • NETD 227.7K
  • DERM 233.2K
  • Earning Date
  • NETD 01-01-0001
  • DERM 11-12-2025
  • Dividend Yield
  • NETD N/A
  • DERM N/A
  • EPS Growth
  • NETD N/A
  • DERM N/A
  • EPS
  • NETD 0.07
  • DERM N/A
  • Revenue
  • NETD N/A
  • DERM $59,399,000.00
  • Revenue This Year
  • NETD N/A
  • DERM $26.16
  • Revenue Next Year
  • NETD N/A
  • DERM $45.27
  • P/E Ratio
  • NETD $170.65
  • DERM N/A
  • Revenue Growth
  • NETD N/A
  • DERM 2.82
  • 52 Week Low
  • NETD $10.72
  • DERM $3.54
  • 52 Week High
  • NETD $11.75
  • DERM $9.40
  • Technical
  • Relative Strength Index (RSI)
  • NETD 60.39
  • DERM 48.08
  • Support Level
  • NETD $11.30
  • DERM $7.42
  • Resistance Level
  • NETD $11.75
  • DERM $8.18
  • Average True Range (ATR)
  • NETD 0.09
  • DERM 0.49
  • MACD
  • NETD 0.02
  • DERM -0.11
  • Stochastic Oscillator
  • NETD 48.89
  • DERM 27.00

About NETD Nabors Energy Transition Corp. II

Nabors Energy Transition Corp II is a blank check company.

About DERM Journey Medical Corporation

Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.

Share on Social Networks: